FDA Approves Centanafadine, First-in-Class NDSRI Drug for ADHD in Adults and Children

When people think about treating attention-deficit/hyperactivity disorder (ADHD), they usually assume there are only two paths. On one side are traditional stimulants—medications like Adderall or Ritalin that work quickly to sharpen focus but can leave patients wrestling with anxiety, sleep disruption, or a harsh emotional crash at the end of the day. On the other side are non-stimulants, which carry fewer side effects but often take weeks to build up in the system and sometimes fail to provide the same level of cognitive clarity. This binary choice has defined ADHD care for decades, leaving many patients feeling stuck between effectiveness and tolerability.

That long-standing binary is officially shifting. On July 24, 2026, the U.S. Food and Drug Administration (FDA) approved centanafadine, which will be sold under the brand name Simtriyo. Developed by Otsuka Pharmaceutical, the once-daily extended-release capsule is approved for adults, adolescents, and children aged six and older who weigh at least 44 pounds.[1][3]

What makes this approval a landmark moment is not just that it is a new pill, but that it introduces an entirely new class of medication to the ADHD toolkit. Simtriyo is the first-ever norepinephrine, dopamine, and serotonin reuptake inhibitor (NDSRI) cleared for this condition. By targeting three distinct chemical pathways at once, it aims to address both the cognitive and emotional facets of ADHD.[1]

To understand why a triple-action approach matters, it helps to look at the mechanics of the ADHD brain. Traditional stimulants work primarily by blocking the reabsorption of dopamine and norepinephrine. Dopamine acts as the brain's reward and motivation center, while norepinephrine acts as the brain's alarm system, promoting alertness. By keeping more of these neurotransmitters active in the synapses, standard medications help patients sustain attention and control impulses.

However, ADHD is rarely just a disorder of focus. Many individuals with the condition also struggle profoundly with emotional dysregulation—experiencing intense frustration, rapid mood swings, or severe anxiety. Traditional stimulants do not directly target the neural pathways responsible for these emotional responses, and in some cases, the surge of norepinephrine can actually make anxiety worse.

This is where Simtriyo's mechanism diverges. As an NDSRI, it inhibits the reuptake of dopamine and norepinephrine, but it also inhibits the reuptake of serotonin. Serotonin is the neurotransmitter most closely associated with mood stabilization, emotional resilience, and calmness. By modulating serotonergic tone alongside the other two chemicals, the medication theoretically offers a smoother, more emotionally balanced profile.[3]

The clinical evidence supporting this new approach is substantial. The FDA's approval was backed by four pivotal Phase 3 clinical trials that spanned the entire age spectrum of ADHD patients, from young children to adults. In these double-blind, placebo-controlled studies, researchers measured symptom reduction using standardized clinical rating scales.[1][3]

The results demonstrated that patients taking Simtriyo experienced statistically significant improvements in their ADHD symptoms compared to those taking a placebo. Crucially for patients who have been frustrated by the slow onset of non-stimulants, the data showed that these improvements began to separate from the placebo group as early as the first week of treatment.[3][4]

The trials also highlighted improvements beyond just core attention metrics. Post-hoc analyses of the adult data presented at clinical conferences suggested that patients experienced meaningful gains in self-reported executive function and emotional regulation, aligning with the theoretical benefits of adding serotonin to the mix.[1]

However, the introduction of any new medication requires a clear-eyed look at its limitations and regulatory realities. For years during its development, many in the psychiatric community anticipated that centanafadine would be classified as a non-stimulant. The FDA's final labeling overturned that expectation.[5]

The agency has officially classified Simtriyo as a central nervous system (CNS) stimulant. Consequently, it carries the same strict boxed warnings as traditional ADHD medications, including alerts regarding the potential for abuse, misuse, and addiction. Furthermore, the label includes a boxed warning for pediatric suicidal ideation, a precaution often attached to medications that influence serotonin.[3][5]

Because of its classification as a CNS stimulant with abuse potential, Simtriyo cannot be prescribed or dispensed immediately. The U.S. Drug Enforcement Administration (DEA) must first assign it a controlled substance schedule. Until that scheduling is finalized—expected later in 2026—the drug remains unavailable at pharmacies, and the exact logistical rules for prescribing it remain unknown.[5]

From a practical standpoint, patients and parents should also be aware of the side effect profile observed in the trials. While generally well-tolerated, the medication is not without drawbacks. In children and adolescents, the most common adverse events included decreased appetite, nausea, rash, and abdominal pain.[2][4]

In adults, the side effect profile looked slightly different, with headache, decreased appetite, insomnia, and dry mouth being the most frequently reported issues. Notably, the medication is not recommended for children under six years old or those weighing less than 44 pounds (20 kg), primarily due to the risk of weight loss observed in pediatric cohorts.[2][3]

Furthermore, because Simtriyo influences serotonin, patients who are already taking selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs) for depression or anxiety will need careful medical supervision. Combining these medications carries a theoretical risk of serotonin syndrome, a rare but serious condition caused by excessive serotonin accumulation.[5]

So, what should a patient or caregiver actually do with this information? If your current ADHD treatment is working well, providing good focus without intolerable side effects, there is no clinical reason to disrupt a successful regimen just because a new drug has been approved. Novelty does not automatically mean superiority for every individual.

However, if you or your child have historically struggled with the harsh emotional blunting of traditional stimulants, or if existing medications have exacerbated anxiety and mood swings, Simtriyo represents a genuinely new pharmacological option to discuss with your doctor. It offers a scientifically distinct mechanism that may finally address the emotional dysregulation that makes ADHD so challenging to navigate.